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We have examined ystrophin mRNA in embryonic, newborn and adult mouse skeletal muscle. A discrete nerve-indepen- 
dent increase in mRNA size was observed between embryonic and adult stages, indicating that a developmentally regulat- 
ed mRNA isoform switch occurs in the expression of the Duchenne muscular dystrophy (DMD) gene in skeletal muscle. 
These distinct mRNAs are most likely generated via selection of alternative transcriptional start sites or RNA processing 
pathways. In addition, denervation of adult muscle was without effect on the expression pattern. 
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1. INTRODUCTION 
Duchenne and Becker muscular dystrophies 
(DMD and BMD) are allelic, X-chromosome link- 
ed, degenerative diseases of skeletal muscle, and 
represent one of the most common potentially 
lethal genetic disorders in man [ 11. The 
DMD/BMD gene is composed of some 60 exons 
spread across an unusually large genomic locus of 
over 2 megabase pairs which encodes an mRNA(s) 
of approximately 14 kb in both humans and mice 
[2-41. Primary structure analyses [5] and immuno- 
localization studies [6-S] have suggested that the 
protein product of the DMD gene, called 
dystrophin [9], is a 125 nm rod-shaped molecule 
associated in a periodic manner with the sub- 
plasmalemmal cytoskeleton of skeletal muscle. 
Dystrophin has been characterized as a single or 
doublet band of approximately 400 kDa by 
Western immunoblotting expressed at quan- 
titatively similar levels in all physiological types of 
embryonic and adult muscle, including skeletal, 
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smooth and cardiac tissues [lo]. At the RNA level, 
however, significant quantitative discrepancies ex- 
ist in the levels of DMD gene expression during 
muscle development and between muscle types. 
Thus, relative to adult skeletal and cardiac muscle, 
embryonic and newborn skeletal and adult smooth 
muscle tissues contain very little dystrophin 
mRNA [3,11]. Furthermore, in a fashion 
analogous to skeletal muscle tissue, an apparent 
developmental activation of dystrophin mRNA ex- 
pression occurs during myoblast to myotube tran- 
sition in cultures of human and mouse skeletal 
muscle [ll-131. 
These apparent discrepancies in DMD gene ac- 
tivity between protein and mRNA levels may 
reflect the existence of distinct mRNA isoforms 
with differing intrinsic translational efficiencies in 
immature compared to adult skeletal muscle, and 
also in mature smooth versus skeletal tissues. 
Based on minor size differences in Western im- 
munoblot analyses, Hoffman et al. [lo] have in- 
deed postulated the existence of such a distinct 
smooth muscle dystrophin isoform. However, at 
present, the paradox of dystrophin polypeptide 
and mRNA levels during development of skeletal 
muscle remains unresolved. Thus, in this report, 
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we have examined the level and size of dystrophin 
mRNA in embrvonic, newborn and adult mouse 
mRNA was prepared from skeletal muscle tissues by extrac- 
tion in 6 M urea and selective precipitation with 3 M LiCl as _ _ 
skeletal muscle, and also following sciatic nerve described [14], and poly(A)+ RNA isolated by oligo(dT)- 
section. Nerve-independent increases in both 
cellulose affinity chromatography. For Northern blot analyses, 
mRNA abundance and size were observed during 
poly(A)+ RNA samples (2-10 cg) were suspended in water, an 
aliauot (0.2-2 ua) taken for examination bv non-denaturing 
myogenesis, clearly demonstrating the existence of 
distinct embryonic and adult dystrophin mRNA 
isoforms. 
2. MATERIALS AND METHODS 
Skeletal muscle tissue samples were dissected from hind limbs 
of embryonic, newborn and adult mice, immediately frozen in 
liquid Nz and stored at - 80°C. For denervation studies, mice 
were anaesthetized and a segment removed from the sciatic 
, -I 
ethidium-agarose electrophoresis, and the remainder denatured 
by glyoxylation, resolved on 0.8% agarose gels and blotted to 
Genescreen transfer membrane (NEN [14]). Northern blot 
filters were orobed seauentiallv bv hvbridization to 32P-labelled 
cDNAs fo; dystrophin (4.j kb insert from Cf23 [15]), 
glyceraldehyde-3-phosphate dehydrogenase (GPDH [16]) and 
the neural cell adhesion molecule (N-CAM, h 9.5 [17]). 
Hybridizations were performed at 42°C in the presence of 50% 
(v/v) formamide and 10% (w/v) dextran sulphate, and washed 
and autoradiographed as described [14]. Bound probe was 
removed from filters prior to subsequent hybridization by 
washing at 70°C for 60 min in 50% formamide, 1 x SSC. nerve as described [18]. 
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Fig. 1. Dystrophin mRNA levels increase during skeletal muscle development. Poly(A)+ RNA was prepared from 16 day embryonic 
(lane l), newborn (lane 2) and adult (lane 3) mouse skeletal muscle. Aliquots were examined by neutral gel electrophoresis (panel A, 
2 ,ug) or glyoxal-gel electrophoresis (8 cg) and sequential Northern blot hybridization with dystrophin (B), GPDH (C) and N-CAM 
(D) cDNA probes. Autoradiographic exposures were for 4 days (B,D) and 4 h (C). The positions of 28 S and 18 S RNAs (arrows) 
and hybridization signals (*) are marked. 
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3. RESULTS 
In order to examine dystrophin mRNA expres- 
sion during skeletal muscle development, poly(A)+ 
RNA was prepared using mouse hind limb skeletal 
muscle from 16 day embryos and from newborn 
and adult (9 weeks) animals. These samples were 
analysed by Northern blotting and filter hybridiza- 
tion with human cDNA probes for dystrophin 
[15], GPDH [la] and N-CAM mRNAs [17]. N- 
CAM and GPDH mRNA levels are known to be 
repressed and activated respectively during skeletal 
muscle development [16,18,19]. In addition, 
characteristic N-CAM mRNA isoform switching 
occurs around the perinatal stages (fig. 1, panels C 
and D) which correlates with myotube formation 
[ 19,201. Subsequent down-regulation of N-CAM 
gene expression occurs in an innervation- 
dependent fashion in adult muscle [21]. The N- 
CAM and GPDH probes thus control the quality 
and developmental source of the muscle RNAs. As 
shown in fig.1 (panel B), while a 14 kb dystrophin 
Fig.2. Distinct dystrophin mRNAs in embryonic and adult 
skeletal muscle. Aliquots of poly(A)+ RNA from embryonic 
(lOpg), newborn (2.5rg) and adult (2.5rg) skeletal muscle 
were prepared and l/10 examined by neutral gel electrophoresis 
(panel A, lanes l-3 respectively). The remainder of the samples 
were subjected to glyoxal-gel electrophoresis, Northern blotting 
and filter hybridization with the dystrophin probe (pane B, lane 
1, embryonic; lane 2, newborn; lane 3, adult samples). 
Autoradiographic exposure was 14 days. 
transcript is clearly present in adult muscle, only 
very low levels were present in embryonic and 
newborn tissue samples. In addition, an apparent 
increase in dystrophin mRNA size was observed in 
embryonic compared to adult tissue samples. In- 
creased loading of embryonic RNA samples clearly 
confirmed a reproducible switch in dystrophin 
mRNA size occurring between embryonic and 
newborn stages of skeletal myogenesis (fig.2). 
During development, qualitative and quan- 
titative changes in a wide range of contractile ap- 
paratus and other cytoplasmic and membrane- 
associated muscle proteins can be broadly clas- 
sified as activity (nerve)-dependent or independent 
[22-241. To examine further the observed develop- 
mental changes in dystrophin mRNA, groups of 
mice were subjected to sciatic nerve section and 
RNA prepared from denervated lower hind-limb 
muscle groups after various periods. As shown in 
fig.3, denervation periods of up to 7 days were 
without major effects on dystrophin (panel B) or 
GPDH (panel D) mRNA levels. However, marked 
and reproducible reactivation of 5.2 and 2.9 kb N- 
CAM mRNA species occurred by 3 days, clearly 
indicating the denervated status and appropriate 
molecular responses of the tissues examined. Ex- 
pression of the DMD/BMD gene in skeletal muscle 
thus appears to be nerve-independent. 
4. DISCUSSION 
The occurrence of distinct embryonic and adult 
isoforms is a common feature of many 
developmentally regulated proteins and has been 
documented for cytosolic, plasma membrane and 
in particular contractile and cytoskeletal proteins 
[23,25,26]. At the nucleic acid level isoform diver- 
sity results from the differential activation of 
members of multigene families, or by the use of 
alternative transcriptional start sites or RNA splic- 
ing and polyadenylation pathways within a single 
but complex gene transcriptional unit [27]. The 
present study provides evidence that dystrophin 
mRNAs occur as embryonic and adult isoforms in 
mouse skeletal muscle and that isoform switching 
occurs during the perinatal period in an 
innervation-independent manner. 
The existence of embryonic and adult mRNA 
isoforms suggests an explanation for observed 
discrepancies in the relative levels of dystrophin 
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Fig.3. Dystrophin mRNA expression is unaffected by denervation. Poly(A)+ RNA was prepared from control skeletal muscle (lane 
1) and following 1 day (lane 2), 3 days (lane 3) or 7 days (lane 4) of denervation. Aliquots were examined by neutral gel electrophoresis 
(panel A, 1 ,ug) or by glyoxal-gel electrophoresis (8 cg) and sequential Northern blot hybridization with dystrophin (B), GPDH (C) 
and N-CAM (D) cDNA probes. Autoradiographic exposures were for 4 days (B,D) or 4 h (C). The positions of 28 S and 18 S mRNA 
are arrowed. 
protein detected by Western immunoblotting and 
dystrophin mRNA on Northern blots of em- 
bryonic, newborn and adult mouse skeletal muscle 
[3,10]. Thus, the smaller embryonic dystrophin 
mRNA, while present in lower abundance than its 
larger adult counterpart may exhibit higher 
translational efficiency. In this way, comparable 
levels of indistinguishable embryonic and adult 
dystrophin polypeptides might be observed in 
Western immunoblot analyses of the respective 
tissues. Furthermore, the developmental increase 
in skeletal muscle in mRNA levels seen here cor- 
relates with the observation that well- 
differentiated cultures of human and mouse 
myotubes express relatively high dystrophin 
mRNA levels compared with undifferentiated 
myoblast progenitor cells [ 1 l- 131. 
At the nucleic acid level, it is generally accepted 
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that, despite its unusually large size, the 
DMD/BMD gene represents a single genetic locus 
[2,28]. The present study thus implies that dif- 
ferent mRNA isoforms must arise in a 
developmentally regulated fashion either via selec- 
tion of alternative promoters of different 
strengths, or via differential RNA processing 
pathways which promote stabilization of the adult 
mRNA isoform. The use of Sl-nuclease protection 
analyses across dystrophin cDNA and genomic 
fragments to examine the nucleotide sequences of 
embryonic compared to adult mRNAs will allow 
these possibilities to be resolved. 
The relationship between the mRNA isoforms 
observed here and dystrophin polypeptide struc- 
ture remains as yet undefined. The existence of a 
distinct smooth muscle isoform has been suggested 
from minor size variations around 400 kDa in 
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Western immunoblot studies [lo]. In another re- 
cent study, using fractionated extracts of skeletal 
muscle a 210 kDa protein reactive with a 
dystrophin peptide antibody, but absent in 
dystrophic muscle, was reported [7]. Dystrophin 
polypeptides are also expressed in cardiac and 
neural tissues. Resolution of protein isoforms and 
correlation with mRNA sub-types may require, 
however, detailed information on differential pro- 
tein coding sequences coupled to subsequent Nor- 
them and Western blot analyses with specific 
oligonucleotide and anti-peptide antibody probes. 
From primary sequence analyses, dystrophin has 
been suggested to be a rod-shaped molecule of 
125 nm [5] associated in a periodic manner with 
the membrane cytoskeleton [6,29] and involved in 
the maintenance of membrane structural integrity 
in the face of mechanical stress [5,30]. Thus, dif- 
ferential isoform expression may reflect changing 
requirements in relation to myofibre structure, or 
differential association with sarcolemmal com- 
ponents, during myofibre development. Indeed, a 
number of major developmental events occur in 
the early postnatal period of myofibre formation 
in the mouse including changes in t-tubule 
organisation and establishment of monosynaptic 
innervation and fibre type distribution [3 l-331. 
Furthermore, in the MDX mouse, pathological 
change is first observed during this period [34]. It 
remained to be seen, however, whether dystrophin 
isoform shifts are causally or temporally 
associated with these events. 
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